Investigation of HER-2 status, treatment response and survival analysis in cervical cancer patients
Por:
Taja-Chayeb, Lucia, Cetina, Lucely, Cruz-Velazquez, Judith, Perez-Montiel, Delia, Moreno-Soriano, Norma, Jimenez-Lima, Roberto, Rivera-Marquez, Raul, Trejo-Becerril, Catalina, Perez-Cardenas, Enrique, Delia Chavez-Blanco, Alma, Dominguez-Gomez, Guadalupe, Duenas-Gonzalez, Alfonso
Publicada:
15 dic 2020
Resumen:
Anti-HER2 therapy has shown benefit in breast and gastric cancers that
over-express HER2; therefore, it is critical to determine whether HER2
is over-expressed and amplified in cervical cancer with current
FDA-approved tests, as previous works have reported frequencies of
over-expression varying from 0% to 77%. We analyzed 100 consecutive
patients starting in January 2013. Patients were previously untreated
and diagnosed with locally advanced cervical cancer. They received
chemoradiation as definitive treatment. We analyzed their primary tumors
with HercepTest and HER-2/neu FISH probe, observing a strong adherence
to the testing and reporting recommendations for HER2 testing in breast
cancer by the American Society of Clinical Oncology. Among 100 patients,
accrued 88 had both tests performed. We found 26 (29.5%) FISH-positive
cases. HercepTest scores rating 0+, 1+, 2+, and 3+ were observed in
65.3%, 11.5%, 7.6% and 15.3% in the 26 FISH-positive. There was no
concordance between the results of both tests using Cohen's Kappa
statistics, neither correlation between FISH status with age, FIGO
stage, and response. FISH-positive patients had a non-statistical
significant trend for worst 4-year survival. The HER2 protein is
over-expressed in only a small subset of invasive cervical cancer as
analyzed by Hercept test. Unexpectedly, HER2 gene amplification occurred
in around 29.5% of cases. We stress that analyzed HER2 status with the
validated methods for the procedures and reports used for breast cancer.
Our results must be seen with caution and must encourage further testing
in a higher number of patients and different populations to confirm our
findings.
Filiaciones:
Taja-Chayeb, Lucia:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Cetina, Lucely:
Inst Nacl Cancerol, Div Clin Res, San Fernando 22, Mexico City 14080, DF, Mexico
Cruz-Velazquez, Judith:
Inst Nacl Cancerol, Unit Diag & Hematol Support, Cytogenet & Mol Biol, San Fernando 22, Mexico City 14080, DF, Mexico
Perez-Montiel, Delia:
Inst Nacl Cancerol, Dept Pathol, San Fernando 22, Mexico City 14080, DF, Mexico
Moreno-Soriano, Norma:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Jimenez-Lima, Roberto:
Inst Nacl Cancerol, Div Clin Res, San Fernando 22, Mexico City 14080, DF, Mexico
Rivera-Marquez, Raul:
Inst Nacl Cancerol, Div Clin Res, San Fernando 22, Mexico City 14080, DF, Mexico
Trejo-Becerril, Catalina:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Perez-Cardenas, Enrique:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Delia Chavez-Blanco, Alma:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Dominguez-Gomez, Guadalupe:
Inst Nacl Cancerol, Div Bas Res, San Fernando 22, Mexico City 14080, DF, Mexico
Duenas-Gonzalez, Alfonso:
Univ Nacl Autonoma Mexico, Inst Invest Biomed, Unit Biomed Res Canc, Inst Nacl Cancerol, Coyoacan 04510, Mexico City 14080, DF, Mexico
|